SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (1744)2/17/1999 12:14:00 AM
From: Bob Swift  Respond to of 10280
 
[12 Month Price Objective: $125-130]

At the rate SEPR is appreciating, 12 days is more like it.



To: Ed Ajootian who wrote (1744)2/17/1999 9:33:00 AM
From: Biomaven  Read Replies (1) | Respond to of 10280
 
From the ML report:

Sepracor expects up to 13 drugs to be
marketed either by partners or directly by the
company by 2002.

The SEPR presentation talks about 13 NDA's by 2002, not 13 marketed drugs.

Don't believe the ML version, and the SEPR version is also probably too aggressive in that it assumes nothing goes even slightly wrong with any of the programs, which is unrealistic.

Push this target out a year and I might believe it.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News